ELIZABETH DIECKMANN: Open Payments
NPI 1336927300 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,924 in 132 payments from 17 companies in 2025. Trend: 2023 $162 · 2024 $1,447 · 2025 $1,924
Food & beverage: $1,800Education: $124
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 29 | $378 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $314 |
| Otsuka America Pharmaceutical, Inc. | 15 | $221 |
| Neurocrine BioSciences, Inc. | 13 | $199 |
| Alkermes, Inc. | 11 | $170 |
| ABBVIE INC. | 13 | $149 |
| Axsome Therapeutics, Inc. | 4 | $69 |
| Corium, LLC | 6 | $67 |
| Supernus Pharmaceuticals, Inc. | 4 | $66 |
| Janssen Pharmaceuticals, Inc | 4 | $64 |
Products named: FANAPT, CAPLYTA, REXULTI, INGREZZA, VRAYLAR, ARISTADA, Auvelity, Azstarys.
Industry payments across IN — which companies pay providers there.
